News | Myriad Genetics

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

Dec 19, 2022 | Corporate

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

Dec 08, 2022 | Products

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

Nov 29, 2022 | Products | Corporate

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

Nov 17, 2022 | Products

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

Nov 14, 2022 | Products

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

Nov 10, 2022 | Products | Pipeline

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

Nov 03, 2022 | Products

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

Nov 01, 2022 | Pipeline | Products

Myriad Genetics Reports Third Quarter Financial Results

Nov 01, 2022 | Financial

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

Oct 31, 2022 | Corporate

Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

Oct 26, 2022 | Financial

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

Sep 28, 2022 | Corporate

New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients

Aug 31, 2022 | Products

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Aug 25, 2022 | Pipeline

Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe

Aug 16, 2022 | Products

Myriad Genetics Reports Second Quarter Financial Results

Aug 04, 2022 | Financial

Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022

Jul 28, 2022 | Financial

Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022

Jul 19, 2022 | Financial

Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial

Jul 12, 2022 | Products

Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

Jun 28, 2022 | Corporate

Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration

Jun 23, 2022 | Pipeline | Products

Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

Jun 09, 2022 | Corporate

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

May 26, 2022 | Corporate

Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022

May 05, 2022 | Financial

Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

May 04, 2022 | Corporate

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

May 03, 2022 | Pipeline | Corporate

Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022

Apr 28, 2022 | Financial | Corporate

2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment

Apr 26, 2022 | Products

Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care

Mar 14, 2022 | Corporate | Products

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

Mar 11, 2022 | Products

Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies

Mar 08, 2022 | Corporate

Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference

Mar 02, 2022 | Corporate

Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives

Feb 24, 2022 | Financial

New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test

Feb 23, 2022 | Products

Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022

Feb 16, 2022 | Corporate | Financial

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

Feb 14, 2022 | Corporate

Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference

Jan 05, 2022 | Corporate | Financial

Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

Jan 04, 2022 | Corporate

DAY HIGH

YEAR HIGH

DAY LOW

YEAR LOW

News Releases

Select year

Categories

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

Myriad Genetics Reports Third Quarter Financial Results

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe

Myriad Genetics Reports Second Quarter Financial Results

Myriad Genetics to Release 2022 Second-Quarter Financial Results on Aug. 4, 2022

Myriad Genetics to Share Update on Business Transformation, Research and Development Pipeline, and Growth Plans at Investor Day on Aug. 11, 2022

Access to Myriad Genetics’ GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial

Myriad Genetics Issues Inaugural Environmental, Social and Governance Report

Myriad Genetics Teams Up with Epic to Make Genetic Testing Accessible to More Patients with Electronic Health Record (EHR) Integration

Myriad Genetics CEO Paul Diaz to Speak at Goldman Sachs 43rd Annual Global Healthcare Conference

Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022

Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022

Myriad Genetics CEO Paul Diaz to Speak at Bank of America Securities 2022 Healthcare Conference

Myriad Genetics Expands Partnership with Intermountain Precision Genomics to Add Liquid Biopsy Therapy Selection Offering to Portfolio of Precise™ Oncology Solutions

Myriad Genetics to Release First-Quarter 2022 Financial Results on May 5, 2022

2 Out of 3 Women With Depression or Anxiety Say They’ve Reached Their “Breaking Point” Yet More than Half Wait a Year Before Seeking Treatment

Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies

Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference

Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives

New Analysis Published in Peer-reviewed Psychiatry Research Shows Advantages of Combinatorial Algorithm of GeneSight® Psychotropic Test

Myriad Genetics to Release Fourth-Quarter 2021 Financial Results on February 24, 2022

Myriad Genetics to Present at Two Upcoming Healthcare Conferences

Myriad Genetics CEO Paul Diaz to Speak at 40th Annual J.P. Morgan Health Care Conference

Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service